Analyzing system consists of a small and portable analyzer and plastic microcuvettes. The microcu...
FDA Device Recall #Z-0619-2013 — Class III — November 7, 2012
Recall Summary
| Recall Number | Z-0619-2013 |
| Classification | Class III — Low risk |
| Date Initiated | November 7, 2012 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | HemoCue AB |
| Location | Angelholm, N/A |
| Product Type | Devices |
| Quantity | 48 affected analyzers |
Product Description
Analyzing system consists of a small and portable analyzer and plastic microcuvettes. The microcuvette contains reagents deposited on its inner walls. The urine sample is drawn into the cavity by capillary action. The filled cuvette is inserted into the device where the contents of the cuvette are mixed through vibration. Within 90 seconds, the immunochemical reaction is completed and the turbidity is measured photometrically at 610 nm. The albumin concentration is proportional to the turbidity. When the end point is reached, the result is displayed in mg/L. The system can be used for the quantitative determination of low levels of albumin in urine for the purpose of screening for, diagnosing, monitoring and to supplement the clinical evidence in the treatment of microalbuminuria.
Reason for Recall
Incorrect version of Quick Reference Guide (QRG) was delivered with products in shipment made from April1 st 2011 and onwards. In addition, a warranty statement was missing in the analyzer package.
Distribution Pattern
Distributed in the states of FL, MA, CA, OR, NY, NC, MO, ID, IN, KY, PA, TX, OK, IL, GA, KS, and UT.
Lot / Code Information
See serial numbers of affected devices in attachment profided by firm.
Other Recalls from HemoCue AB
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2070-2025 | Class II | The HemoCue Glucose 201 Microcuvettes are desig... | May 12, 2025 |
| Z-0101-2014 | Class II | HemoCue¿ Hb 201 Microcuvettes, carton/4 boxes/2... | Jul 25, 2013 |
| Z-0086-2014 | Class II | HemoCue¿ Urine Albumin Microcuvettes, 25 Microc... | Jul 16, 2013 |
| Z-2190-2013 | Class II | HemoCue¿ Glucose 201 Microcuvettes, 25 Microcuv... | Jul 15, 2013 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.